| Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (NCT07371585) | SOLTI Breast Cancer Research Group | 2026-02-18 |
| Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain (NCT06991946) | SOLTI Breast Cancer Research Group | 2025-05-20 |
| HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (NCT06236269) | SOLTI Breast Cancer Research Group | 2024-03-15 |
| Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102) (NCT05885009) | SOLTI Breast Cancer Research Group | 2023-03-28 |
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (NCT05982093) | SOLTI Breast Cancer Research Group | 2023-02-03 |
| NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (NCT05569811) | SOLTI Breast Cancer Research Group | 2022-11-25 |
| Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (NCT05296746) | SOLTI Breast Cancer Research Group | 2022-05-03 |
| Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (NCT05207709) | SOLTI Breast Cancer Research Group | 2022-03-28 |
| Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (NCT05340413) | SOLTI Breast Cancer Research Group | 2022-03-25 |
| Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer (NCT04759248) | SOLTI Breast Cancer Research Group | 2021-03-15 |
| Elacestrant in Preoperative Setting, a Window of Opportunity Study (NCT04797728) | SOLTI Breast Cancer Research Group | 2021-02-09 |
| A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (NCT04610528) | SOLTI Breast Cancer Research Group | 2020-12-22 |
| Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer (NCT04142892) | SOLTI Breast Cancer Research Group | 2020-11-06 |
| Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer (NCT04497285) | SOLTI Breast Cancer Research Group | 2020-10-20 |
| Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer (NCT04460430) | SOLTI Breast Cancer Research Group | 2020-07-23 |
| Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression (NCT04251169) | SOLTI Breast Cancer Research Group | 2020-07-21 |
| Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC (NCT04142060) | SOLTI Breast Cancer Research Group | 2020-06-01 |
| Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (NCT04253561) | SOLTI Breast Cancer Research Group | 2020-02-25 |
| HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a) (NCT04257162) | SOLTI Breast Cancer Research Group | 2019-12-13 |
| Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy (NCT04130152) | SOLTI Breast Cancer Research Group | 2019-11-21 |